Psychedelic‐inspired approaches for treating neurodegenerative disorders

Saeger, Hannah N.; Olson, David E.

doi:10.1111/jnc.15544

Cited by 26 publications

(16 citation statements)

References 332 publications

(428 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lucke-Wold B MedPress Publications LLC and tau hyperphosphorylation and accumulation [6]. Psychedelic medications are promising therapeutics in CTE for their ability to treat neuropsychiatric deficits and ability to promote neuroplasticity and suppress neuroinflammation and neurodegeneration [73][74][75][76][77][78][79][80][81][82][83][84].…”

Section: Medpress Psychiatry and Behavioral Sciencesmentioning

confidence: 99%

Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy

Fusco¹,

Olowofela²,

Dagra³

et al. 2022

MPPBS

View full text Add to dashboard Cite

show abstract

Section: Medpress Psychiatry and Behavioral Sciencesmentioning

confidence: 99%

Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy

Fusco¹,

Olowofela²,

Dagra³

et al. 2022

MPPBS

View full text Add to dashboard Cite

show abstract

“…Brain-derived neurotrophic factor (BDNF) is a key neuroplasticity-modulating neurotrophin that is involved in many physiological and pathological brain processes ( 221 , 222 ). It has been reported that psychedelics and related compounds, inducing the activation of AMPA and NMDA receptors, can positively modulate the levels of BDNF and/or neurotrophins which, inducing neuroplasticity, would ameliorate disorders originating from altered neuronal connectivity ( 223 ). For example, a single, low dose of LSD acutely increases BDNF levels in healthy volunteers ( 224 ).…”

Section: Psychedelicsmentioning

confidence: 99%

3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs

et al. 2022

View full text Add to dashboard Cite

The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of efficacy, delayed onset of action or side effects. Psychoactive substances have a long history of being used as tools to alter consciousness and as a gateway to approach the unknown and the divinities. These substances were initially obtained from plants and animals and more recently by chemical synthesis, and its consumption evolved toward a more recreational use, leading to drug abuse-related disorders, trafficking, and subsequent banning by the authorities. However, these substances, by modulation of certain neurochemical pathways, have been proven to have a beneficial effect on some psychiatric disorders. This evidence obtained under medically controlled conditions and often associated with psychotherapy, makes these substances an alternative to conventional medicines, to which in many cases the patient does not respond properly. Such disorders include post-traumatic stress disease and treatment-resistant depression, for which classical drugs such as MDMA, ketamine, psilocybin and LSD, among others, have already been clinically tested, reporting successful outcomes. The irruption of new psychoactive substances (NPS), especially during the last decade and despite their recreational and illicit uses, has enlarged the library of substances with potential utility on these disorders. In fact, many of them were synthetized with therapeutic purposes and were withdrawn for concrete reasons (e.g., adverse effects, improper pharmacological profile). In this review we focus on the basis, existing evidence and possible use of synthetic cathinones and psychedelics (specially tryptamines) for the treatment of mental illnesses and the properties that should be found in NPS to obtain new therapeutic compounds.

show abstract

“…Most current psychedelic research is focused on the potential therapeutic effects of these compounds. In particular, studies suggest that psychedelics may be an effective treatment for a variety of clinical issues, including treatment-resistant depression (Carhart-Harris et al, 2021), cancer-related distress (Griffiths et al, 2016;Ross et al, 2016), obsessive compulsive disorder (Moreno et al, 2006), substance use disorders (Bogenschutz et al, 2015(Bogenschutz et al, , 2018Johnson, Garcia-Romeu, & Griffiths, 2017), eating disorders (Spriggs, Kettner, & Carhart-Harris, 2020), and neurodegenerative disorders (Saeger & Olson, 2021). Psychedelics have also been posited to promote healthy lifestyle changes (Lutkajtis, 2021;Madsen et al, 2020;Teixeira et al, 2022), increase nature-relatedness (Lyons & Carhart-Harris, 2018) and foster environmental virtues (Kirkham & Letheby, 2022).…”

Section: Introductionmentioning

confidence: 99%

Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands

Lutkajtis

Evans

2023

JPS

View full text Add to dashboard Cite

This article reports on integration challenges that were experienced by nine individuals who attended a three-day legal psilocybin truffle retreat in the Netherlands. The study employed a qualitative phenomenological approach, using semi-structured interviews to gain an understanding of participants' (n = 30) psilocybin experiences and their after-effects. While the study did not actively seek to measure integration issues or unexpected side effects, nine out of thirty participants (30%) spontaneously reported a post-experience integration challenge. These challenges included: mood fluctuations, ‘post-ecstatic blues’, disconnection from community, re-experiencing symptoms, spiritual bypass and perceived lack of support. Integration challenges were transient; they occurred immediately after the psilocybin experience (once the main psychedelic effects had worn off) and in the days and weeks following the retreat, and resolved with time. Integration challenges were also correlated with positive after-effects including long-term remission of significant health conditions. The experiences related in this article align with existing literature that describes the ‘spiritual emergency’ phenomenon; that is, the potential challenges that can arise after ecstatic experiences and how these challenges may be integral to the transformative potential of such experiences. We discuss the implications for psychedelic integration and harm reduction practices and for future psychedelic research.

show abstract

Psychedelic‐inspired approaches for treating neurodegenerative disorders

Abstract: The atrophy of dendritic arbors, loss of dendritic spines, and reduction of synapse density in cortical regions controlling cognition, memory, and mood are hallmarks of Alzheimer's disease (AD), frontotemporal dementia (FTD), and related neurodegenerative dis-

Cited by 26 publications

References 332 publications

Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy

Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy

3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs

Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands

Contact Info

Product

Resources

About